Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03353740 · ClinicalTrials.gov registry record · Phase 3
Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence
A Phase 3 study, sponsored by Thomas Hope.
- Completed
- Registry status
- Phase 3
- Development phase
- 346
- Enrollment target
NCT03353740 is a Phase 3 study that has completed, run by Thomas Hope. The registered enrollment target is 346 participants.
The verdict
NCT03353740, a Phase 3 study, has completed, sponsored by Thomas Hope.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 346 participants
- Enrollment target
Study Summary
The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detection prostate cancer in patients with biochemical recurrence after prostatectomy and radiation therapy.
Interventions
- DRUG Ga-68 labeled PSMA-11 PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 346 participants |
| Start Date | 2017-09-20 |
| Est. Completion | 2020-09-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03353740
The ClinicalTrials.gov registry entry for NCT03353740 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 346 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Hope, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ga-68 labeled PSMA-11 PET is the first listed.
NCT03353740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03353740 about?
NCT03353740 is a clinical study titled "Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence". The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detection prostate cancer in patients with biochemical recurrence after prostatectomy and radiation therapy.
What is the current status of trial NCT03353740?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 346 participants. The study started on 2017-09-20. Estimated completion is 2020-09-01.
What interventions are being tested in trial NCT03353740?
The interventions under investigation include: Ga-68 labeled PSMA-11 PET (DRUG).
Who is sponsoring clinical trial NCT03353740?
This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.